Three-Year trial tests best dose to protect lungs in genetic emphysema
NCT ID NCT07326592
Summary
This study aims to find the most effective weekly dose of Respreeza or Zemaira to slow the progression of lung damage in adults with emphysema caused by Alpha-1 antitrypsin deficiency. Over 270 participants will receive one of three different doses via weekly intravenous infusions for three years. Researchers will compare how well each dose preserves lung density and reduces severe breathing flare-ups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA1 ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.